Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.79%56 3-Year Revenue Growth Rate is 10.10% as of Dec. 2025, which is 94% above its 10-year median of 5.20. GuruFocus rates XMAD:LAB with a GF Score™ of 56/100 and a GF Value™ of €3.60 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 904 Drug Manufacturers companies, Labiana Health ranks better than 72.23% on this metric.
During the past 12 months, Labiana Health's average Revenue per Share Growth Rate was 16.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Labiana Health was 10.10% per year. The lowest was 0.40% per year. And the median was 5.20% per year.
Labiana Health (XMAD:LAB) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Labiana Health 3-Year Revenue Growth Rate Related Terms
XMAD:LAB vs ZTS, UTHR, VTRS: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Labiana Health's 3-Year Revenue Growth Rate falls into.
Labiana Health 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 10.10% mean?
Labiana Health (XMAD:LAB) has a 3-Year Revenue Growth Rate of 10.10% as of Dec. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Labiana Health and its competitors. This is 94% above median its historical median of 5.20. Over the past decade, Labiana Health's 3-Year Revenue Growth Rate has ranged from 0.40 to 10.10. According to the industry distribution chart, Labiana Health ranks #251 out of 904 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Labiana Health's 3-Year Revenue Growth Rate too high?
Labiana Health's current 3-Year Revenue Growth Rate of 10.10% is 94% above median its 10-year median of 5.20. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 10.10. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.80. Labiana Health's value of 10.10% is 165.8% above this industry median. Based on the distribution chart, Labiana Health ranks #251 out of 904 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's 3-Year Revenue Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #251 out of 904 companies for 3-Year Revenue Growth Rate. This puts Labiana Health in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.80. Labiana Health's value of 10.10% is 165.8% above this benchmark. Historically, Labiana Health's own 3-Year Revenue Growth Rate has ranged from 0.40 to 10.10 over the past decade. While the company's 10-year median is 5.20 vs. the industry median of 3.80, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.80, based on 904 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current 3-Year Revenue Growth Rate of 10.10% is 165.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Labiana Health and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current 3-Year Revenue Growth Rate is 10.10%, which is 94% above median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.60, compared to a current price of €6.30 — trading 75% above its estimated fair value. The current 3-Year Revenue Growth Rate is 10.10%, which is 94% above median its 10-year median of 5.20 and 165.8% above the Drug Manufacturers industry median of 3.80. Labiana Health's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current 3-Year Revenue Growth Rate is 10.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.30 is trading 75% above its estimated GF Value™ of €3.60.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
3-Year Revenue Growth Rate: 10.10% (94% above median its 10-year median of 5.20)
GF Value™: €3.60 vs. price of €6.30 (75% above fair value)
Industry Position: 165.8% above the Drug Manufacturers median (#251 of 904)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
56GF Score
Get the complete analysis for XMAD:LAB
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
